Mission Therapeutics is a private, drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat diseases of high unmet need.
Mission has built a world-leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.
Mission’s DUB platform is yielding a rich pipeline of novel therapeutics for the benefit of patients across therapeutic areas.
Mission’s strategy is to create value by advancing its pipeline programmes through early clinical development, and preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy.
Mission’s leadership team has a wealth of international, commercial and scientific experience, and the company has strong links with key academic and research centers including Cancer Research UK Laboratories and the Jackson Laboratories at the Gurdon Institute, University of Cambridge.
The Company has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015.
In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. Mission is based at the Babraham Research Campus, south of Cambridge.
Location: United Kingdom, England, Cambridgeshire
Employees: 51-200
Total raised: $178.62M
Founded date: 2011
Investors 2
Date | Name | Website |
- | Sofinnova ... | sofinnovap... |
- | SR One | srone.com |
Funding Rounds 6
Date | Series | Amount | Investors |
14.03.2024 | - | $32.25M | - |
06.07.2020 | - | $15M | - |
02.02.2016 | - | $86.47M | - |
25.09.2015 | Grant | $2.88M | - |
18.11.2013 | Series B | $32.23M | - |
26.08.2011 | Series A | $9.79M | - |
Mentions in press and media 19
Date | Title | Description | Source |
14.03.2024 | Mission Therapeutics Raises £25.2M in Funding | Mission Therapeutics, a Cambridge, UK-based clinical-stage biotech company developing therapeutics t... | finsmes.co... |
09.08.2021 | Mission and AbbVie collaboration in Alzheimer’s and Parkinso... | Mission and AbbVie collaboration in Alzheimer’s and Parkinson’s diseases reaches next milestone 09-0... | cambridgen... |
10.07.2020 | BioMed Realty fully leases flagship life sciences developmen... | BioMed Realty fully leases flagship life sciences development at Babraham Research Campus within 12 ... | cambridgen... |
06.07.2020 | Mission raises $15m and expands its relationship with Pfizer | Mission raises $15m and expands its relationship with Pfizer 06-07-2020 Mission Therapeutics, a drug... | cambridgen... |
06.07.2020 | Mission Therapeutics Raises $15M in Funding | Mission Therapeutics, a Cambridge, England-based drug discovery and development company focused on s... | finsmes.co... |
06.07.2020 | Mission raises $15m and expands its relationship with Pfizer | Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deu... | cambridgen... |
06.07.2020 | IP GROUP PLC IP : Mission Therapeutics Ltd - Mission Raises... | Mission Therapeutics ('Mission'), a drug discovery and development company focused on selectively in... | marketscre... |
04.12.2019 | Mission and AbbVie’s collaboration in Alzheimer’s and Parkin... | Mission and AbbVie’s collaboration in Alzheimer’s and Parkinson’s diseases reaches milestone 04-12-2... | cambridgen... |
17.10.2019 | BioMed Realty announces first lettings at Babraham Research ... | BioMed Realty announces first lettings at Babraham Research Campus in Cambridge 17-10-2019 Set to op... | cambridgen... |
17.10.2019 | BioMed Realty announces first lettings at Babraham Research ... | Set to open in April 2020, BioMed Realty's Babraham Research Campus buildings are now more than 50% ... | cambridgen... |
Show more